Please visit answersincme.com/AZB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Salman R. Punekar, MD, MSc. In this activity, an expert in the management of non–small-cell lung cancer (NSCLC) discusses the unmet treatment needs with current RAS(OFF) inhibitors and the potential role for emerging next-generation RAS(ON) inhibitors in KRAS-mutant NSCLC. Upon completion of this activity, participants should be better able to: Describe the persistent unmet needs in KRAS-mutant NSCLC, highlighting treatment gaps across diverse KRAS variants in pretreated advanced settings; Summarize the potential advantages of next-generation RAS(ON) inhibitors versus RAS(OFF) inhibitors; and Evaluate the future positioning of RAS(ON) inhibitors in clinical practice based on emerging evidence.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related